Fly News Breaks for December 13, 2018
NBIX
Dec 13, 2018 | 07:39 EDT
Oppenheimer analyst Jay Olson lowered his price target for Neurocrine to $105 from $140 after T-Force-GOLD missed the primary endpoint, sending the shares down on the loss of this important opportunity in Tourette syndrome. The analyst reiterates an Outperform rating on the shares.
News For NBIX From the Last 2 Days